Loading
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Stock: price and insider trades · China
迪哲医药
No insider purchase over the last 90 days. The latest, by SHIH-YING CHANG, was filed 21 Aug 2025.
Insider Decl.
27
Thresholds
n/a
Buy Volume
€5M
3 ops. · all time
Sell Volume
€30M
24 ops. · all time
Who traded when
BuySale张小林7 sales
Xiaolin Zhang6 sales
Honchung Tsui(徐汉忠)4 sales
Shih-Ying Chang1 buy3 sales
Qingbei Zeng2 sales
张知为1 sale
+1 other insider
Since the insiders bought
- -21.8%Entry CN¥83.30 · Close at T+90 CN¥65.11
- +30.3%Entry CN¥32.97 · Close at T+365 CN¥42.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,049 of 26,250 companies
30.5
score / 100
Value26
Quality35
FCF yld-2.7%
Earn yld-2.7%
EV/EBITDA·
ROE-44%
Gross mgn96%
Net mgn-95%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥61.43
Analyst consensus
1 analystsCN¥83.00Target CN¥83.00(+35%)CN¥83.00
Income statement
RevenueCN¥801.1M
Gross profitCN¥766.9M96% margin
EBITDA-CN¥667.2M-83% margin
Net income-CN¥764M-61.6% margin
Valuation
PER (forward)93.1x
P/Book25.3x
Beta-0.01
Balance sheet & cash
Market capCN¥28.6B
Total debtCN¥1.2B
Free Cash Flow-CN¥758.8M
Debt / Equity120%
Profitability & ownership
ROE-43.7%
ROA-13.7%
% insiders41.1%
% institutions35.8%
Last declaration on 16 October 2026
Declarations27 total
352,488 shares@ CN¥471.19419.2% of flowA股XSHGSSE:273000001733579680
251,001 shares@ CN¥453.741516.3% of flowA股XSHGSSE:273000001721657470
559,092 shares@ CN¥461.070544.0% of flowA股XSHGSSE:273000001716568030
557,260 shares@ CN¥456.673678.2% of flowA股XSHGSSE:273000001704624030
5,000 shares@ CN¥450.6942100.0% of flowA股XSHGSSE:273000001704615550
11,230 shares@ CN¥450.39617.1% of flowA股XSHGSSE:273000001699555330
143,977 shares@ CN¥454.373297.9% of flowA股XSHGSSE:273000001694330600
3,118 shares@ CN¥450.5431100.0% of flowA股XSHGSSE:273000001645513900
194,163 shares@ CN¥427.4295100.0% of flowA股XSHGSSE:273000001609500860
200 shares1.9% of flowA股XSHGSSE:173000009384407520
Canonical exit: 19 Nov 2025 (T+90)
2,500 shares3.0% of flowA股XSHGSSE:173000009275968160
75,000 shares88.4% of flowA股XSHGSSE:173000009275962660
84,500 shares99.4% of flowA股XSHGSSE:173000009276160220
4,000 shares4.6% of flowA股XSHGSSE:173000009272439100
500 shares0.6% of flowA股XSHGSSE:173000009263231460
3,500 shares4.1% of flowA股XSHGSSE:173000009263140640
800 shares6.0% of flowA股XSHGSSE:173000009168679700
10,380 shares71.2% of flowA股XSHGSSE:173000009149794270
2,975 shares20.9% of flowA股XSHGSSE:173000009141554700
481,145 shares18.6% of flowA股XSHGSSE:173000008927375300
375,578 shares15.4% of flowA股XSHGSSE:173000008927386270
398,705 shares16.5% of flowA股XSHGSSE:173000008921305570
150,257 shares5.4% of flowA股XSHGSSE:173000008803439580
151,563 shares5.4% of flowA股XSHGSSE:173000008794927600
236,004 shares9.0% of flowA股XSHGSSE:173000008772566530
25 of 27 declarations
About Dizal (Jiangsu) Pharmaceutical Co., Ltd.
The 27 filings of 迪哲医药 (Dizal (Jiangsu) Pharmaceutical Co., Ltd.) were published between February 5, 2024 and October 16, 2026, and 24 of them are sales, worth EUR 30.3 million in total with a median of EUR 806,820. The two most recent are also among the largest: EUR 4,584,848 on October 14, 2026 and EUR 4,555,482 on October 13, 2026, in the name of 张小林 (董事, 高级管理人员, 核心技术人员). Another, EUR 3,164,384 on May 7, 2025, is filed under the name Xiaolin Zhang.
The 3 purchases weigh EUR 5 million (median EUR 662,158), or 11% of open-market trades. The largest, EUR 4,385,070, is Xiaolin Zhang's on February 5, 2024, followed by EUR 662,158 on February 8, 2024; Shih-Ying Chang bought EUR 1,972 on August 21, 2025.
Read moreShow less
The year 2025 has 16 filings, against 2 in 2024. Filings appear a median of 0 days after the trade, that is, the same day. This Chinese healthcare company, listed on the Shanghai Stock Exchange, is worth CNY 28.6 billion, with 41.1% of the capital held by insiders. The 9 filings of the last twelve months are all sales.
